Disclosure Of First-Time Adoption [Text Block]

Hyloris Pharmaceuticals SA - Filing #3166256

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31
Disclosure of first-time adoption [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity	55,045,000 EUR	—	—	476,000 EUR	121,513,000 EUR	1,622,000 EUR	64,246,000 EUR	140,000 EUR	4,460,000 EUR	54,805,000 EUR	476,000 EUR	—	—	48,056,000 EUR	—	3,827,000 EUR	103,693,000 EUR	2,391,000 EUR	—	129,000 EUR	—	—	43,226,000 EUR	129,000 EUR	3,827,000 EUR	476,000 EUR	1,814,000 EUR	103,693,000 EUR	59,059,000 EUR
Comprehensive income	—	10,770,000 EUR	10,770,000 EUR	—	—	—	—	—	—	—	—	- EUR	- EUR	—	- EUR	—	—	—	- EUR	—	11,579,000 EUR	11,579,000 EUR	—	—	—	—	—	—	—
Profit (loss)	—	10,770,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	11,579,000 EUR	—	—	—	—	—	—	—	—